Siteman Cancer Center

Siteman Cancer Center researcher Alexander Stegh, PhD, and colleagues at Washington University School of Medicine in St. Louis have developed a noninvasive nanotherapy for brain cancer delivered through nasal drops. The novel delivery method is less invasive than similar treatments in development and was shown in mice to effectively treat glioblastoma by boosting the brain’s immune response. This work redefines how immunotherapy can reach otherwise difficult-to-treat tumors. 🔗 https://lnkd.in/gZi2znqr

The FDA has granted breakthrough therapy designation to WU-CART-007, a novel off-the-shelf CAR T-cell therapy developed by Washington University School of Medicine in St. Louis researchers at Siteman Cancer Center. In early global trials, 73% of adults and adolescents with certain blood cancers achieved full remission. This is just one of several practice-changing advances coming out of Siteman. https://lnkd.in/g_SQyX7h

We’re proud to see Siteman Cancer Center’s Dr. Premal Thaker, chief of Gynecologic Oncology at Washington University School of Medicine in St. Louis and an internationally recognized leader in the field, weighing in on this important FDA approval. The approval of pembrolizumab for platinum-resistant ovarian cancer is a meaningful step forward for patients with limited treatment options.

February is National Cancer Prevention Month. At Siteman Cancer Center, prevention is one of our deepest commitments. According to our 8IGHTWAYS® program, a large percentage of cancers and many other chronic diseases can be prevented through eight evidence-based behaviors: maintaining a healthy weight, exercising regularly, not smoking, eating a healthy diet, limiting alcohol, protecting your skin, knowing your family history and getting screened. Even small changes can have a big impact. And these are things within your control. https://lnkd.in/gYQJcm_J

Colorectal cancer is now the No. 1 cause of cancer death in the U.S. for those under age 50.⁠ Siteman Cancer Center is leading the way in treatment and prevention. The Young-Onset Colorectal Cancer Program at Siteman is one of the first in the country to focus exclusively on providing care for colorectal cancer patients under 50 while addressing concerns that are especially important to younger people. And we have developed a tool, Your Disease Risk, that helps determine your individual risk of colorectal cancer and other diseases and offers personalized tips to help prevent them. Learn more: • How Should Younger Adults Think About Colorectal Cancer? https://bit.ly/49Rm9uC • Your Disease Risk https://bit.ly/4q9NixG • Young-Onset Colorectal Cancer Program https://bit.ly/4qcOKzk

More people are surviving cancer longer. Huge applause to WashU Medicine researchers and clinicians at Siteman for pushing the limits on new advancements and helping achieve a significant increase in survival rates for all cancers, as the American Cancer Society (ACS) reports in new national data. At Siteman Cancer Center, our community of survivors continues to grow.   • Learn more from the ACS: https://lnkd.in/g-YsVV5D • Siteman’s Survivorship Program is another great resource: https://lnkd.in/gGXnBN53

The Gary C. Werths Building at Siteman Cancer Center has been recognized for its advanced architecture in terms of sustainability and environmental impact — earning LEED Gold certification. The space is intentionally designed to be the most ergonomic for clinical research and collaboration as well as the most reassuring and calming for patients, families, caregivers and staff. The Werths Building is our newest location, an integral part of what makes Siteman the region’s top choice for cancer care by providing accessible multidisciplinary treatment in a thoughtfully designed environment — another way Siteman leads in healing beyond medicine. Learn more: https://lnkd.in/gqR3Xymk

***Newest Breakthrough*** In the most recent collaboration by WashU Medicine researchers at Siteman Cancer Center, a national team of scientists has created the most detailed “atlas” yet of immune cells inside the bone marrow of people with multiple myeloma — and it’s changing how we understand this rare blood cancer that currently has no cure. The researchers found that certain immune cells can predict survival and relapse at the time of diagnosis. These unparalleled new insights may: • Improve survival predictions • Better guide treatment decisions • Lead to the development of new immune-based therapies Advances like this bring us closer to longer survival, fewer relapses and more precise care for patients.

WashU Medicine researchers at Siteman Cancer Center helped drive a record $1.7 billion in private-sector investment this past year — from startup companies built on WashU discoveries. Beyond science, this surge is transforming the St. Louis region — creating high-quality jobs, attracting global investors and anchoring a growing biotech hub centered on improving human health. The takeaway? Research at Siteman is saving more lives than ever — and at the same time, catalyzing more innovation, more investment and more economic growth. At Siteman and WashU, the “virtuous cycle” of discovery → translation → impact is evident, and patients everywhere are benefiting.

Travis, a patient with metastatic bladder cancer, shares his secret to staying grounded: a dedicated hour to worry and wonder. One hour every two weeks opens up space for more life and renews his ability to stay positive. It's a practice he credits to his time with Siteman nurses. Watch or listen to the most recent "This Is Cancer" episode, which also features his WashU Medicine medical oncologist Dr. Reimers, wherever you get your podcasts: https://bit.ly/4qfaJX4 . . . #thisiscancer #bladdercancerawareness #bladdercancer #metastaticcancer #metastaticcancerawareness #metastaticbladdercancer #washumedicine #oncologynurses